IL114152A - Preparation of stable zinc insulin analog crystals - Google Patents

Preparation of stable zinc insulin analog crystals

Info

Publication number
IL114152A
IL114152A IL11415295A IL11415295A IL114152A IL 114152 A IL114152 A IL 114152A IL 11415295 A IL11415295 A IL 11415295A IL 11415295 A IL11415295 A IL 11415295A IL 114152 A IL114152 A IL 114152A
Authority
IL
Israel
Prior art keywords
preparation
insulin analog
zinc insulin
stable zinc
analog crystals
Prior art date
Application number
IL11415295A
Other languages
English (en)
Other versions
IL114152A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22990041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL114152(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL114152A0 publication Critical patent/IL114152A0/xx
Publication of IL114152A publication Critical patent/IL114152A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL11415295A 1994-06-16 1995-06-14 Preparation of stable zinc insulin analog crystals IL114152A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,647 US5504188A (en) 1994-06-16 1994-06-16 Preparation of stable zinc insulin analog crystals

Publications (2)

Publication Number Publication Date
IL114152A0 IL114152A0 (en) 1995-10-31
IL114152A true IL114152A (en) 1999-12-31

Family

ID=22990041

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11415295A IL114152A (en) 1994-06-16 1995-06-14 Preparation of stable zinc insulin analog crystals

Country Status (29)

Country Link
US (1) US5504188A (en:Method)
EP (1) EP0692489B1 (en:Method)
JP (1) JP3595607B2 (en:Method)
KR (1) KR100369951B1 (en:Method)
CN (1) CN1184234C (en:Method)
AT (1) ATE233278T1 (en:Method)
AU (1) AU697794B2 (en:Method)
BR (1) BR9502798A (en:Method)
CA (1) CA2151563C (en:Method)
CO (1) CO4410205A1 (en:Method)
CZ (1) CZ286066B6 (en:Method)
DE (1) DE69529708T2 (en:Method)
DK (1) DK0692489T3 (en:Method)
ES (1) ES2188637T3 (en:Method)
FI (1) FI952930L (en:Method)
HU (1) HUT73495A (en:Method)
IL (1) IL114152A (en:Method)
IN (1) IN178919B (en:Method)
MY (1) MY130551A (en:Method)
NO (1) NO952334L (en:Method)
NZ (1) NZ272358A (en:Method)
PE (1) PE21896A1 (en:Method)
PL (1) PL180968B1 (en:Method)
RO (1) RO113529B1 (en:Method)
RU (1) RU2156257C2 (en:Method)
SI (1) SI0692489T1 (en:Method)
TW (1) TW379228B (en:Method)
YU (1) YU39595A (en:Method)
ZA (1) ZA954942B (en:Method)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
EP0969860B1 (en) * 1997-03-20 2002-07-17 Novo Nordisk A/S Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
AU1375199A (en) * 1997-11-12 1999-05-31 Alza Corporation Method for decreasing self-association of polypeptides
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
JP2002527488A (ja) * 1998-10-16 2002-08-27 ノボ ノルディスク アクティーゼルスカブ メントールを含有する肺送達のためのインスリン製剤
DE69920767T2 (de) * 1998-10-16 2006-02-02 Novo Nordisk A/S Stabile konzentrierte Insulin Präparationen zur pulmonaren Verabreichung
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
EP1346726A4 (en) * 2000-12-25 2004-09-15 Shiseido Co Ltd Sympathetic-activating perfume composition
ATE349469T1 (de) * 2001-02-09 2007-01-15 Genentech Inc Kristallisierung von igf-1
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
US7601688B2 (en) * 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
EP2239012A3 (en) 2003-04-11 2011-06-15 High Point Pharmaceuticals, LLC Substituted amide derivatives and pharmaceutical uses thereof
CN102784386A (zh) 2003-11-20 2012-11-21 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
EP2626368B1 (en) 2004-07-19 2016-12-21 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008513356A (ja) * 2004-08-09 2008-05-01 アリオス バイオファーマ インク． 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
KR101286569B1 (ko) 2005-07-04 2013-07-23 하이 포인트 파마슈티칼스, 엘엘씨 신규 약제
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
ES2393757T3 (es) 2005-11-17 2012-12-27 Eli Lilly & Company Antagonistas de receptor de glucagón, preparación y usos terapéuticos
JP5312054B2 (ja) 2006-03-15 2013-10-09 ノボ・ノルデイスク・エー／エス アミリンとインスリンの混合物
NZ570524A (en) 2006-03-28 2011-08-26 High Point Pharmaceuticals Llc Benzothiazoles having histamine H3 receptor activity
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
ATE543798T1 (de) 2006-04-24 2012-02-15 Lilly Co Eli Cyclohexyl-substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1
EA016026B1 (ru) 2006-05-29 2012-01-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи 3-(1,3-бензодиоксол-5-ил)-6-(4-циклопропилпиперазин-1-ил)пиридазин, его соли и сольваты и его применение в качестве антагониста н3 рецептора гистамина
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
AU2008257505B2 (en) 2007-06-01 2013-05-16 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
CA2702892C (en) * 2007-10-16 2017-02-28 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
EP2337563B1 (en) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
BRPI1007457A2 (pt) 2009-01-28 2015-08-25 Smartcells Inc Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
WO2010107519A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
MX346473B (es) * 2009-08-11 2017-03-22 Biocon Ltd Procesos cromatograficos y compuestos purificados de los mismos.
KR20140007377A (ko) 2011-02-01 2014-01-17 노보 노르디스크 에이/에스 인슐린의 정제
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
EP2925345B1 (en) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CN103342746B (zh) * 2013-07-26 2014-07-30 珠海联邦制药股份有限公司 一种制备稳定的门冬胰岛素结晶的方法
WO2015084694A2 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
EP2990033A1 (fr) * 2014-08-26 2016-03-02 Carlina Technologies Procédé de préparation de nanoprécipites de peptide ou protéine de faible poids moléculaire
EP3185887B1 (en) 2014-08-26 2021-03-10 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
CN104193819B (zh) * 2014-09-03 2017-05-17 韩飞 胰岛素二聚体晶体的合成和保存方法
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CN104892749B (zh) * 2015-06-16 2019-02-05 珠海联邦制药股份有限公司 一种德谷胰岛素结晶的制备方法及应用
CN105753966A (zh) * 2016-05-05 2016-07-13 通化东宝药业股份有限公司 一种重组人胰岛素结晶的制备方法
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
GB2610490A (en) 2020-03-31 2023-03-08 Protomer Tech Inc Conjugates for selective responsiveness to vicinal diols
IL302775A (en) 2020-11-19 2023-07-01 Protomer Tech Inc Aromatic boron-containing compounds and insulin analogs
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品
KR20250005573A (ko) 2022-05-18 2025-01-09 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 관련 인슐린 유사체

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE515508A (en:Method) *
BE533298A (en:Method) *
BE533252A (en:Method) *
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2920104A (en) 1958-07-01 1960-01-05 Vanderbilt Co R T Stabilized solutions of a dithiocarbamate
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
JPH03506023A (ja) * 1988-07-20 1991-12-26 ノボ　ノルデイスク　アクツイエセルスカプ ポリペプチド
WO1990007522A1 (en) * 1988-12-23 1990-07-12 Novo Nordisk A/S Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
IL110977A (en) * 1993-09-17 2000-06-29 Novo Nordisk As Human insulin derivative and pharmaceutical composition comprising it
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas

Also Published As

Publication number Publication date
PE21896A1 (es) 1996-06-15
CO4410205A1 (es) 1997-01-09
HUT73495A (en) 1996-08-28
KR100369951B1 (ko) 2003-03-28
BR9502798A (pt) 1996-06-04
KR960000922A (ko) 1996-01-25
IN178919B (en:Method) 1997-07-19
EP0692489A1 (en) 1996-01-17
ZA954942B (en) 1996-12-17
DE69529708D1 (de) 2003-04-03
CA2151563A1 (en) 1995-12-17
CN1184234C (zh) 2005-01-12
FI952930A7 (fi) 1995-12-17
PL309099A1 (en) 1995-12-27
FI952930L (fi) 1995-12-17
PL180968B1 (pl) 2001-05-31
DK0692489T3 (da) 2003-03-31
JP3595607B2 (ja) 2004-12-02
CA2151563C (en) 2007-08-07
NO952334L (no) 1995-12-18
TW379228B (en) 2000-01-11
ATE233278T1 (de) 2003-03-15
JPH08169899A (ja) 1996-07-02
AU697794B2 (en) 1998-10-15
CZ154195A3 (en) 1996-02-14
AU2168195A (en) 1996-01-04
RU2156257C2 (ru) 2000-09-20
NO952334D0 (no) 1995-06-13
US5504188A (en) 1996-04-02
CZ286066B6 (cs) 2000-01-12
ES2188637T3 (es) 2003-07-01
EP0692489B1 (en) 2003-02-26
FI952930A0 (fi) 1995-06-14
NZ272358A (en) 1996-12-20
SI0692489T1 (en) 2003-06-30
RO113529B1 (ro) 1998-08-28
HU9501715D0 (en) 1995-08-28
MY130551A (en) 2007-06-29
DE69529708T2 (de) 2003-10-16
CN1128271A (zh) 1996-08-07
IL114152A0 (en) 1995-10-31
YU39595A (sh) 1997-08-22
RU95110107A (ru) 1997-05-10

Similar Documents

Publication Publication Date Title
HU9501715D0 (en) Preparation of stable zinc insulin analog crystals
NZ227429A (en) Wound healing composition comprising purified platelet-derived growth factor and purified transforming growth factor alpha and method of use
HUT52548A (en) Process for production of mini-proinsuline and medical compositions containing them as active substance
IE893444L (en) Method for the treatment of periodontal disease
EP0709395A3 (en) Preparation of Stable Insulin Analog Crystals
HUT51596A (en) Process for production of the active substance of the medical composition levodopa
AU1474788A (en) Crystalline human proinsulin and process for its production
AU3812993A (en) Refolding and purification of insulin-like growth factor I
EP0476875A3 (en) Process for the purification and concentration of biologically active materials
AU9069091A (en) Aramid monofilament with weakly structured skin and process of production thereof
AU7476494A (en) Use of n-methyl-aspartic acid for enhancing growth and altering body composition
AU7800391A (en) Precursor forms of porcine growth hormone releasing factor and related DNA compounds
AU4553593A (en) Treatment of diabetes using phosphorylated insulin
HUT48907A (en) Process for production of small peptides linked to 1,4 receptors with immunogene effect and medical preparatives containing these substances
AU1497792A (en) Precursor form of bovine growth hormone releasing factor and related dna compounds
RO102987B1 (ro) Procedeu de purificare a insulinei
CS237390A2 (en) Method of halohydrogen acids and high-purity diiodohypoiodous acid's production
IE890812L (en) Novel derivative of human growth hormone
CS8902452A1 (en) Method of porcine insulin's analogue preparation
AU8225091A (en) Treatment of a microbial infection with drugs containing para-acetamidobenzoic acid
CS536288A1 (en) Method of oxyhaemoglobin's purified solution preparation
CS497489A2 (en) Method of human insulin's analogues preparation
CS686688A1 (en) Connection of programmable regulator's analogue inputs
HK1028198A (en) Treatment of diabetes with rosiglitazone and insulin

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired